NCT06929650 The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer
| NCT ID | NCT06929650 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Thyroid Nodule |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-04-20 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-04-20 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is: • What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)? Participants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure/intervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.
Eligibility Criteria
Inclusion Criteria: 1\. Patients with: * Nodule less than or equal to 2cm in size a. Specifically: Bethesda 5/6 * Their age is ≥18 years and ≤100 years * Able to provide written consent * Able to attend required follow-ups as per the protocol Exclusion Criteria: * Patients \<18 years old * Pregnant women * Any concern for invasive or metastatic thyroid cancer * Previously treated for thyroid cancer
Contact & Investigator
Jesse D Pasternak, MD, MPH
PRINCIPAL INVESTIGATOR
University Health Network (UHN) Toronto
Frequently Asked Questions
Who can join the NCT06929650 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Thyroid Nodule. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06929650 currently recruiting?
Yes, NCT06929650 is actively recruiting participants. Contact the research team at jesse.pasternak@uhn.ca for enrollment information.
Where is the NCT06929650 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06929650 clinical trial?
NCT06929650 is sponsored by University Health Network, Toronto. The principal investigator is Jesse D Pasternak, MD, MPH at University Health Network (UHN) Toronto. The trial plans to enroll 40 participants.